Skip to main content

Table 1 clinical characteristics and blood lipid level in non-progressive and progressive HCC patients with sorafenib treatment

From: Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma

 

Non-progression (n = 29)

Progression (n = 49)

P

Age(years)

53.17 ± 11.81

53.71 ± 9.78

0.83

Male rate(%)

93.10%

73.47%

0.03*

Drink rate(%)

31.03%

18.37%

0.20

BMI(Kg/m2)

22.64 ± 2.91

22.40 ± 3.13

0.74

TG(mmol/L)

1.10 ± 0.42

1.27 ± 0.53

0.14

TC(mmol/L)

4.17 ± 1.04

4.81 ± 1.48

0.04*

HDL(mmol/L)

1.43 ± 0.41

1.53 ± 0.53

0.48

LDL(mmol/L)

2.37 ± 0.72

2.70 ± 1.18

0.18

AFP(ng/ml)

295.24 ± 408.51

334.80 ± 435.48

0.70

ALT(U/L)

49.82 ± 47.00

55.02 ± 50.37

0.66

AST(U/L)

69.52 ± 69.83

74.34 ± 76.09

0.78

ALB(U/L)

39.46 ± 8.00

39.29 ± 7.81

0.93

  1. BMI BodyMassIndex, TC Total cholesterol, TG Total triglyceride, HDL High-density lipoprotein cholesterol, LDL Low-density lipoprotein cholesterol, AFP Alpha-fetal protein, ALT Glutamic-pyruvic transaminase, AST Glutamic-oxalacetic transaminase, ALB Albumin
  2. Non-progression group: there is no medical imaging progress after a period treatment of sorafenib progression group: there is medical imaging progress after a period treatment of sorafenib
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us